Business
Sanofi in Talks for Partial Sale of Opella to US Private Equity Firm CD&R
PARIS, FRANCE — French pharmaceutical giant Sanofi has entered exclusive negotiations with U.S. private equity firm Clayton Dubilier & Rice (CD&R) regarding the partial sale of its subsidiary, Opella. The talks mark a significant step in Sanofi’s plan to sell a portion of Opella while maintaining a stake in the business.
The announcement follows the French government’s decision to acquire a 2% stake in Opella through the state-owned investment firm Bpifrance. The investment, valued between €100 million and €150 million, will also give the government a seat on Opella’s board.
As part of the deal, CD&R and Sanofi have made several key commitments to safeguard jobs and operations in France. Opella’s workforce in the country will be protected, with a €100,000 penalty for each job lost. The companies also agreed to maintain Opella’s headquarters and research and development (R&D) activities in France, with plans to invest €70 million in the country over the next five years.
The decision to sell a stake in Opella to a U.S. firm has sparked significant backlash in France. Concerns were raised earlier this month about potential job losses and the risk of medicine shortages. These fears have been heightened since the COVID-19 pandemic, which exposed vulnerabilities in pharmaceutical supply chains and led to public calls for increased onshoring of drug production.
Opella, known for producing France’s top-selling painkiller, Doliprane, holds a strong position in the domestic market. The potential sale has raised concerns about the future of French jobs and the stability of drug supplies. However, Sanofi has emphasized that it will retain approximately half of the business, allowing it to remain a key player in Opella’s future.
In its statement, Sanofi noted that the offer from CD&R is “binding and fully financed,” adding that the private equity firm has a long history of investment in Europe, including building French national champions and supporting local employment for over two decades.
Sanofi clarified that by remaining a major shareholder in Opella, it would continue to benefit from the company’s future growth. The partial sale values Opella at around €16 billion.
Pending regulatory approval from the French government, the transaction is expected to be finalized by the second quarter of 2025.
The deal underscores ongoing discussions in France about the importance of safeguarding national interests in critical industries like pharmaceuticals, particularly in light of recent global supply chain disruptions.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
